WallStreetZenWallStreetZen

NASDAQ: ADIL
Adial Pharmaceuticals Inc Stock Ownership - Who owns Adial Pharmaceuticals?

Insider buying vs selling

Have Adial Pharmaceuticals Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Kevin SchuylerDirector2023-09-29700$2.74
$1.92kBuy

1 of 1

ADIL insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ADIL insiders and whales buy or sell their stock.

ADIL Shareholders

What type of owners hold Adial Pharmaceuticals Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Cary J. Claiborne37.49%1,520,000$2.89MInsider
William B. Stilley Iii34.38%1,393,920$2.65MInsider
Bankole A. Johnson21.52%872,720$1.66MInsider
James W. Newman Jr.10.82%438,742$833.61kInsider
Joseph Truluck6.54%265,139$503.76kInsider
Armistice Capital LLC3.92%159,000$302.10kInstitution
Robertson H. Gilliland2.70%109,424$207.91kInsider
Manchester Capital Management LLC1.19%48,097$91.38kInstitution
Renaissance Technologies LLC0.57%23,200$44.08kInstitution
Susquehanna International Group LLP0.36%14,789$28.10kInstitution

1 of 3

ADIL vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ADIL5.41%94.59%Net Buying
TENX7.69%92.31%
PTIX2.55%1.03%Net Buying
CVKD3.45%46.72%Net Buying
PSTV0.60%99.40%Net Buying

Adial Pharmaceuticals Stock Ownership FAQ

Who owns Adial Pharmaceuticals?

Adial Pharmaceuticals (NASDAQ: ADIL) is owned by 6.52% institutional shareholders, 113.90% Adial Pharmaceuticals insiders, and 0.00% retail investors. Cary J. Claiborne is the largest individual Adial Pharmaceuticals shareholder, owning 1.52M shares representing 37.49% of the company. Cary J. Claiborne's Adial Pharmaceuticals shares are currently valued at $2.58M.

If you're new to stock investing, here's how to buy Adial Pharmaceuticals stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.